These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33928571)

  • 1. siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.
    Lu M; Zhang M; Hu B; Huang Y
    Methods Mol Biol; 2021; 2282():77-100. PubMed ID: 33928571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
    Holm A; Løvendorf MB; Kauppinen S
    Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.
    Springer AD; Dowdy SF
    Nucleic Acid Ther; 2018 Jun; 28(3):109-118. PubMed ID: 29792572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.
    Brown CR; Gupta S; Qin J; Racie T; He G; Lentini S; Malone R; Yu M; Matsuda S; Shulga-Morskaya S; Nair AV; Theile CS; Schmidt K; Shahraz A; Goel V; Parmar RG; Zlatev I; Schlegel MK; Nair JK; Jayaraman M; Manoharan M; Brown D; Maier MA; Jadhav V
    Nucleic Acids Res; 2020 Dec; 48(21):11827-11844. PubMed ID: 32808038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.
    Matsuda S; Keiser K; Nair JK; Charisse K; Manoharan RM; Kretschmer P; Peng CG; V Kel'in A; Kandasamy P; Willoughby JL; Liebow A; Querbes W; Yucius K; Nguyen T; Milstein S; Maier MA; Rajeev KG; Manoharan M
    ACS Chem Biol; 2015 May; 10(5):1181-7. PubMed ID: 25730476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity.
    Janas MM; Schlegel MK; Harbison CE; Yilmaz VO; Jiang Y; Parmar R; Zlatev I; Castoreno A; Xu H; Shulga-Morskaya S; Rajeev KG; Manoharan M; Keirstead ND; Maier MA; Jadhav V
    Nat Commun; 2018 Feb; 9(1):723. PubMed ID: 29459660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of siRNA-mediated gene silencing in vivo.
    Zlatev I; Castoreno A; Brown CR; Qin J; Waldron S; Schlegel MK; Degaonkar R; Shulga-Morskaya S; Xu H; Gupta S; Matsuda S; Akinc A; Rajeev KG; Manoharan M; Maier MA; Jadhav V
    Nat Biotechnol; 2018 Jul; 36(6):509-511. PubMed ID: 29786096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.
    Rajeev KG; Nair JK; Jayaraman M; Charisse K; Taneja N; O'Shea J; Willoughby JL; Yucius K; Nguyen T; Shulga-Morskaya S; Milstein S; Liebow A; Querbes W; Borodovsky A; Fitzgerald K; Maier MA; Manoharan M
    Chembiochem; 2015 Apr; 16(6):903-8. PubMed ID: 25786782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.
    Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J
    Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.
    Nair JK; Attarwala H; Sehgal A; Wang Q; Aluri K; Zhang X; Gao M; Liu J; Indrakanti R; Schofield S; Kretschmer P; Brown CR; Gupta S; Willoughby JLS; Boshar JA; Jadhav V; Charisse K; Zimmermann T; Fitzgerald K; Manoharan M; Rajeev KG; Akinc A; Hutabarat R; Maier MA
    Nucleic Acids Res; 2017 Nov; 45(19):10969-10977. PubMed ID: 28981809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization.
    Hofmeister A; Jahn-Hofmann K; Brunner B; Helms MW; Metz-Weidmann C; Krack A; Kurz M; Li Z; Weitzenberg MM; Pflimlin E; Plettenburg O; Scheidler S
    J Med Chem; 2021 May; 64(10):6838-6855. PubMed ID: 33950677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.
    Willoughby JLS; Chan A; Sehgal A; Butler JS; Nair JK; Racie T; Shulga-Morskaya S; Nguyen T; Qian K; Yucius K; Charisse K; van Berkel TJC; Manoharan M; Rajeev KG; Maier MA; Jadhav V; Zimmermann TS
    Mol Ther; 2018 Jan; 26(1):105-114. PubMed ID: 28988716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
    Nair JK; Willoughby JL; Chan A; Charisse K; Alam MR; Wang Q; Hoekstra M; Kandasamy P; Kel'in AV; Milstein S; Taneja N; O'Shea J; Shaikh S; Zhang L; van der Sluis RJ; Jung ME; Akinc A; Hutabarat R; Kuchimanchi S; Fitzgerald K; Zimmermann T; van Berkel TJ; Maier MA; Rajeev KG; Manoharan M
    J Am Chem Soc; 2014 Dec; 136(49):16958-61. PubMed ID: 25434769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic siRNA: State-of-the-Art and Future Perspectives.
    Friedrich M; Aigner A
    BioDrugs; 2022 Sep; 36(5):549-571. PubMed ID: 35997897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.
    Foster DJ; Brown CR; Shaikh S; Trapp C; Schlegel MK; Qian K; Sehgal A; Rajeev KG; Jadhav V; Manoharan M; Kuchimanchi S; Maier MA; Milstein S
    Mol Ther; 2018 Mar; 26(3):708-717. PubMed ID: 29456020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference in the era of nucleic acid therapeutics.
    Jadhav V; Vaishnaw A; Fitzgerald K; Maier MA
    Nat Biotechnol; 2024 Mar; 42(3):394-405. PubMed ID: 38409587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonuclease.
    Kumar P; Degaonkar R; Guenther DC; Abramov M; Schepers G; Capobianco M; Jiang Y; Harp J; Kaittanis C; Janas MM; Castoreno A; Zlatev I; Schlegel MK; Herdewijn P; Egli M; Manoharan M
    Nucleic Acids Res; 2020 May; 48(8):4028-4040. PubMed ID: 32170309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs.
    Schlegel MK; Matsuda S; Brown CR; Harp JM; Barry JD; Berman D; Castoreno A; Schofield S; Szeto J; Manoharan M; Charissé K; Egli M; Maier MA
    Nucleic Acids Res; 2021 Nov; 49(19):10851-10867. PubMed ID: 34648028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.